Literature DB >> 33851146

SARS-COV-2 ANTIBODY PREVALENCE AMONG HEALTHCARE WORKERS AND FIRST RESPONDERS, FLORIDA, MAY-JUNE 2020.

James Matthias1, Emma C Spencer2, Mara Michniewicz2, Thomas M Bendle3, Craig Wilson2, Kenneth A Scheppke2, Carina Blackmore2, Aaron Otis1, Scott A Rivkees2.   

Abstract

BACKGROUND: The SARS-CoV-2 virus responsible for severe respiratory infection associated with coronavirus disease 2019 (COVID-19) was first confirmed in Florida on March 1, 2020. Responding to the pandemic, multi-agency collaborative partnerships put in place actions integrating point-of-care antibody testing at established large-scale COVID-19 testing sites where the baseline seropositivity of COVID-19 in health care workers and first responders in Florida at the start of the pandemic was established.
PURPOSE: Determine the seropositivity of healthcare workers and first responders at five drive thru testing sites using a rapid SARS-CoV-2 antibody test in Florida from May 6 through June 3, 2020.
METHODS: The first drive-thru SARS-CoV-2 antibody test site was opened at Miami Hard Rock Stadium, May 6, 2020. Testing expanded to three additional sites on May 9, 2020: Jacksonville, Orlando, and Palm Beach. The fifth and final site, Miami Beach, began testing on May 21, 2020. Healthcare workers and first responder's self-seeking SARS-CoV-2 testing were designated for antibody testing and completed a laboratory collection form onsite for the point-of-care test. All testing was performed on whole blood specimens (obtained by venipuncture) using the Cellex Inc. qSARS-CoV-2 IgG/IgM Rapid Test. Seropositivity was assessed by univariate analysis and by logistic regression including the covariates age, sex, race/ethnicity, and testing location. RESULTS AND DISCUSSION: As of June 3, 2020, of 5,779 healthcare workers and first responders tested, 4.1% were seropositive (range 2.6-8.2%). SARS-COV-2 antibody tests had higher odds of being positive for persons testing at the Miami Hard Rock Stadium (aOR 2.24 [95% C.I. 1.48-3.39]), persons of Haitian/Creole ethnicity (aOR 3.28 [95% C.I. 1.23-8.72]), Hispanic/Latino(a) ethnicity (aOR 2.17 [95% C.I. 1.50-3.13], and Black non-Hispanic persons (aOR 1.63 [95% C.I. 1.08-2.46]). SARS-COV-2 antibody prevalence among first responders and healthcare workers in five sites in Florida varied by race and ethnicity and by testing location.

Entities:  

Year:  2021        PMID: 33851146      PMCID: PMC8040388     

Source DB:  PubMed          Journal:  Fla Public Health Rev


  16 in total

1.  COVID-19 Serosurveillance May Facilitate Return-to-Work Decisions.

Authors:  Martin Krsak; Steven C Johnson; Eric M Poeschla
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

2.  Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.

Authors:  Neeraj Sood; Paul Simon; Peggy Ebner; Daniel Eichner; Jeffrey Reynolds; Eran Bendavid; Jay Bhattacharya
Journal:  JAMA       Date:  2020-06-16       Impact factor: 56.272

3.  Seroprevalence of Dengue and Zika Virus in Blood Donations: A Systematic Review.

Authors:  Stephanie M Eick; Ariella Perry Dale; Brian McKay; Casey Lawrence; Mark H Ebell; José F Cordero; Michael Welton
Journal:  Transfus Med Rev       Date:  2018-10-31

4.  Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.

Authors:  Fiona P Havers; Carrie Reed; Travis Lim; Joel M Montgomery; John D Klena; Aron J Hall; Alicia M Fry; Deborah L Cannon; Cheng-Feng Chiang; Aridth Gibbons; Inna Krapiunaya; Maria Morales-Betoulle; Katherine Roguski; Mohammad Ata Ur Rasheed; Brandi Freeman; Sandra Lester; Lisa Mills; Darin S Carroll; S Michele Owen; Jeffrey A Johnson; Vera Semenova; Carina Blackmore; Debra Blog; Shua J Chai; Angela Dunn; Julie Hand; Seema Jain; Scott Lindquist; Ruth Lynfield; Scott Pritchard; Theresa Sokol; Lynn Sosa; George Turabelidze; Sharon M Watkins; John Wiesman; Randall W Williams; Stephanie Yendell; Jarad Schiffer; Natalie J Thornburg
Journal:  JAMA Intern Med       Date:  2020-07-21       Impact factor: 21.873

5.  Drive-through medicine: a novel proposal for rapid evaluation of patients during an influenza pandemic.

Authors:  Eric A Weiss; Jessica Ngo; Gregory H Gilbert; James V Quinn
Journal:  Ann Emerg Med       Date:  2010-01-15       Impact factor: 5.721

Review 6.  Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Authors:  Evan M Bloch; Shmuel Shoham; Arturo Casadevall; Bruce S Sachais; Beth Shaz; Jeffrey L Winters; Camille van Buskirk; Brenda J Grossman; Michael Joyner; Jeffrey P Henderson; Andrew Pekosz; Bryan Lau; Amy Wesolowski; Louis Katz; Hua Shan; Paul G Auwaerter; David Thomas; David J Sullivan; Nigel Paneth; Eric Gehrie; Steven Spitalnik; Eldad A Hod; Lewis Pollack; Wayne T Nicholson; Liise-Anne Pirofski; Jeffrey A Bailey; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

7.  Dengue outbreak in Key West, Florida, USA, 2009.

Authors:  Elizabeth G Radke; Christopher J Gregory; Kristina W Kintziger; Erin K Sauber-Schatz; Elizabeth A Hunsperger; Glen R Gallagher; Jean M Barber; Brad J Biggerstaff; Danielle R Stanek; Kay M Tomashek; Carina G M Blackmore
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

8.  Drive-Through COVID-19 Testing During the 2020 Pandemic: A Safe, Efficient, and Scalable Model for Pediatric Patients and Health Care Workers.

Authors:  Erin F Flynn; Elizabeth Kuhn; Mohammed Shaik; Elizabeth Tarr; Nicole Scattolini; Allison Ballantine
Journal:  Acad Pediatr       Date:  2020-05-29       Impact factor: 3.107

9.  Dengue virus infection in people residing in Africa: a systematic review and meta-analysis of prevalence studies.

Authors:  Fredy Brice N Simo; Jean Joel Bigna; Sebastien Kenmoe; Marie S Ndangang; Elvis Temfack; Paul F Moundipa; Maurice Demanou
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

10.  Convalescent plasma as a potential therapy for COVID-19.

Authors:  Long Chen; Jing Xiong; Lei Bao; Yuan Shi
Journal:  Lancet Infect Dis       Date:  2020-02-27       Impact factor: 25.071

View more
  1 in total

1.  SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021.

Authors:  Anna R Giuliano; Shari Pilon-Thomas; Michael J Schell; Martha Abrahamsen; Jessica Y Islam; Kimberly Isaacs-Soriano; Kayoko Kennedy; Christopher W Dukes; Junmin Whiting; Julie Rathwell; Jonathan A Hensel; Leslie N Mangual; Ernst Schonbrunn; Melissa Bikowitz; Dylan Grassie; Yan Yang
Journal:  Emerg Infect Dis       Date:  2022-01-26       Impact factor: 6.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.